Open AccessMaintenance Therapy for First‐Line Metastatic Colorectal Cancer: Activity and Sustainability
Author(s) -
Strickler John H.,
Hurwitz Herbert I.
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0358
Subject(s) - medicine , bevacizumab , capecitabine , oxaliplatin , colorectal cancer , oncology , regimen , cancer , chemotherapy
Results of a study, published in this issue of The Oncologist , comparing capecitabine and oxaliplatin plus bevacizumab with the same regimen for only six cycles followed by bevacizumab monotherapy in metastatic colorectal cancer patients are examined.